22nd Century Group VP of Regulatory Science to Participate in FDLI Panel in Response to Recent FDA Action on Comprehensive Plan and Reduced Nicotine Mandate Company Supports This Week’s Positive FDA Action on E-Cigarettes, Demonstrating the Agency’s Commitment to Providing Adult Smokers with Alternatives to Highly Addictive CigarettesApplauds FDA’s Active...

22nd Century Group Reports Business Highlights and Financial Results for the Second Quarter 2021 Initiated International Launch Process For VLN®, First Sales Planned by First Quarter 2022First Revenue From Hemp/Cannabis Franchise to Commence in Second Half of 2021Third Plant-Based Franchise to be...

Becerra Confirmation Boosts 22nd Century’s Position to Disrupt Tobacco Industry WILLIAMSVILLE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low...